Antibody biodistribution coefficients: Inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human

Cited by (262)

Items 101–200 of 262

1. Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment
   Vanessa Neiens, Eva-Maria Hansbauer, Thomas J. Jaquin, Janet K. Peper-Gabriel, Poornima Mahavadi, Mark E. Snyder, Maximilian J. Grill, Cornelia Wurzenberger, Antonio D. Konitsiotis, Adriana Estrada‐Bernal et al. · 2025 · Nature Communications
2. Quantitative systems toxicology: modelling to mechanistically understand and predict drug safety
   Christopher E. Goldring, Giusy Russomanno, Carmen Pin, Panuwat Trairatphisan, Kylie A. Beattie, Ciaran P. Fisher, Janet Piñero, Richard Brennan, Diana Clausznitzer, Ian M. Copple et al. · 2025 · Nature Reviews Drug Discovery
3. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
   Richard J. Dimelow, Beulah Ji, Herbert Struemper · 2020 · Clinical Pharmacology in Drug Development
4. Engineering of single-domain antibodies for next-generation snakebite antivenoms
   Carla Freire Celedônio Fernandes, Soraya dos Santos Pereira, Marcos Barros Luiz, Nauanny K.R.L. Silva, Marcela Cristina S. Silva, Anna Carolina Machado Marinho, Marcela Helena Gambim Fonseca, Gilvan Pessoa Furtado, Raphael Trevizani, Roberto Nicolete et al. · 2021 · International Journal of Biological Macromolecules
5. Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling
   Jean‐François Rossi, Hao-Chun Chiang, ZY Lu, Kalle Levón, Frits van Rhee, Karan J. K. Kanhai, David C. Fajgenbaum, Bernard Klein · 2022 · Frontiers in Immunology
6. Nonclinical and clinical characterization of MAU868, a novel human-derived monoclonal neutralizing antibody targeting BK polyomavirus VP1
   Johanna R. Abend, Atul Sathe, Matthias B. Wrobel, Mark S. Knapp, Lucy Xu, Lihong Zhao, Peter Kim, Sachin Desai, Amanda Nguyen, Xavier Charles Leber et al. · 2024 · American Journal of Transplantation
7. Mechanistic Investigation of the Preclinical Pharmacokinetics and Interspecies Scaling of PF-05231023, a Fibroblast Growth Factor 21–Antibody Protein Conjugate
   Craig Giragossian, Chandra Vage, Jun Li, Kathleen B. Pelletier, Nicole Piche‐Nicholas, Manoj Rajadhyaksha, Jennifer L. Liras, Alison Logan, Roberto A. Calle, Yan Weng · 2015 · Drug Metabolism and Disposition
8. The Role of Interleukin-37 in the Pathogenesis of Allergic Diseases
   Igor P. Shilovskiy, M.E. Dyneva, Oksana Mikhaylovna Kurbacheva, Dmitry Anatolievich Kudlay, Musa Rakhimovich Khaitov · 2019 · Acta Naturae
9. Burden of illness among subgroups of patients with primary Sjögren’s syndrome and systemic involvement
   Kerry Gairy, Claudia Knight, P Anthony, Ben Hoskin · 2020 · Lara D. Veeken
10. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice
    Zhe Li, Ying-Yi Li, Hsuan‐Ping Chang, Xiaoying Yu, Dhaval K. Shah · 2021 · Journal of Pharmacokinetics and Pharmacodynamics
11. Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling
    Beverly Knight, Brinda K. Tammara, Nishit B. Modi, Shannon Dallas, Saro Mardirosian, Jianyao Wang, Aline Laenen, Laurent Leclercq, Karen A. Diloreto, Lieve Adriaenssen et al. · 2025 · Dermatology and Therapy
12. Intratumoral Nanofluidic System for Enhancing Tumor Biodistribution of Agonist CD40 Antibody
    Corrine Ying Xuan Chua, Jeremy Ho, Antonia Šušnjar, Graziano Lolli, Nicola Di Trani, Federica Pesaresi, Mengying Zhang, Elizabeth A. Nance, Alessandro Grattoni · 2020 · Advanced Therapeutics
13. The NF-κB/leukemia inhibitory factor/STAT3 signaling pathway in antibody-mediated suppression of Sindbis virus replication in neurons
    Jane X. Yeh, Kimberly L. W. Schultz, Valerie S. Calvert, Emanuel F. Petricoin, Diane E. Griffin · 2020 · Proceedings of the National Academy of Sciences
14. Mathematical modeling of receptor occupancy data: A valuable technology for biotherapeutic drug development
    Mary E. Spilker, Pratap Singh, Paolo Vicini · 2015 · Cytometry Part B Clinical Cytometry
15. Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product
    Shufang Liu, Ekram Ahmed Chowdhury, Vivian Xu, Anthony Jerez, Leeha Mahmood, Bao Quoc Ly, Huyen Khanh Le, Anne Nguyen, Aneesh Rajwade, Guy M. L. Meno‐Tetang et al. · 2023 · Journal of Pharmaceutical Sciences
16. Tau antibody 77G7 targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation
    Longfei Li, Jin Miao, Dandan Chu, Nana Jin, Yunn Chyn Tung, Chun‐Ling Dai, Wen Hui Hu, Cheng‐Xin Gong, Khalid Iqbal, Fei Liu · 2022 · CNS Neuroscience & Therapeutics
17. A sequential dual-locked strategy with pH-responsive activation of photosensitizers and precise Cerenkov radiation delivery for cancer theranostics
    Qinghe Wu, You Zhang, Guoping Jia, Mengfei Hou, Yifei Jiang, Weijun Wei, Ping Liu, Gang Huang, Jianhua Zou, Jingjing Zhang et al. · 2023 · Nano Today
18. Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop
    Logan Banadyga, Wenjun Zhu, Shweta Kailasan, Katie A. Howell, Krzysztof Franaszek, Shihua He, Vinayakumar Siragam, Keding Cheng, Feihu Yan, Estella Moffat et al. · 2021 · mBio
19. Biodistribution of Etanercept to Tissues and Sites of Inflammation in Arthritic Rats
    Xi Chen, Debra C. DuBois, Richard R. Almon, William J. Jusko · 2015 · Drug Metabolism and Disposition
20. Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation
    K. van der Straten, M. V. van Gils, S. D. de Taeye, G. D. de Bree · 2022 · Frontiers in Medical Technology
21. The single‐chain anti‐ TNF ‐α antibody DLX 105 induces clinical and biomarker responses upon local administration in patients with chronic plaque‐type psoriasis
    Athanasios Tsianakas, Patrick Manfred Brunner, Kamran Ghoreschi, C Berger, Karin Loser, Martin Röcken, Georg Stingl, Thomas Anton Luger, Thomas Jung · 2016 · Experimental Dermatology
22. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration
    Bussing, David, Li, Zhe, Li, Yingyi, Chang, Hsuan-Ping, Chang, Hsueh-Yuan, Guo, Leiming, Verma, Ashwni, Shah, Dhaval K. · 2021 · The AAPS Journal
23. Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs
    Matthew J. Krautmann, Rodney R. Walters, Vickie L. King, Kevin Esch, Sean P. Mahabir, Andrea J. Gonzales, Paul J. Dominowski, Laurel M. Sly, Duncan M. Mwangi, Dennis L. Foss et al. · 2023 · Veterinary Immunology and Immunopathology
24. Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
    Tamara Gassner, Christina Chittilappilly, Theo Pirich, Benjamin Neuditschko, Klaus Hackner, Judith Lind, Osman Aksoy, Uwe Graichen, Sascha Klee, Franz Herzog et al. · 2024 · Journal for ImmunoTherapy of Cancer
25. Utilization of physiologically‐based pharmacokinetic model to assess disease‐mediated therapeutic protein‐disease‐drug interaction in immune‐mediated inflammatory diseases
    Lujing Wang, Yang Chen, Wangda Zhou, Xin Miao, Honghui Zhou · 2021 · Clinical and Translational Science
26. Prediction of Cardiac ATTR Depletion by NI006 ( ALXN2220 ) Using Mechanistic PK / PD Modeling
    Aubin Michalon, Lionel Renaud, Matthias Macháček, Cédric Cortijo, Chandrasekhar Udata, Michele F. Mercuri, Fabian Buller, Christoph Höck, Roger M. Nitsch, Peter C. Kahr et al. · 2024 · Clinical Pharmacology & Therapeutics
27. Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model
    Yilin Mao, Elizabeth E. Evans, Vikas A. Mishra, Leslie Balch, Allison Eberhardt, Maurice Zauderer, Wendy Anne Gold · 2021 · International Journal of Molecular Sciences
28. Monoclonal antibody anti-PBP2a protects mice against MRSA (methicillin-resistant Staphylococcus aureus) infections
    Felipe Saraiva, Ana Caroline Cavalcante de Araújo, Anna Érika Vieira de Araújo, Jose Procopio Moreno Senna · 2019 · PLoS ONE
29. Bispecific antibody-derived molecules to target persistent HIV infection
    Jeffrey L. Nordstrom, Guido Ferrari, David M. Margolis · 2022 · Journal of Virus Eradication
30. Impact of charge patches on tumor disposition and biodistribution of therapeutic antibodies
    Jakob C. Stüber, Karin Farah Rechberger, Saša M. Miladinović, Thomas Pöschinger, Tamara Zimmermann, Rémi Villenave, Miro Julian Eigenmann, Thomas E. Kraft, Dhaval K. Shah, Hubert Kettenberger et al. · 2022 · AAPS Open
31. Model-Based Meta-Analysis to Optimize Staphylococcus aureus‒Targeted Therapies for Atopic Dermatitis
    Takuya Miyano, Alan David Irvine, Reiko J. Tanaka · 2022 · JID Innovations
32. Anti-α-synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson's disease
    Robert P. Brendza, Xiaoying Gao, Kimberly L. Stark, Han Lin, Seung-Hye Lee, Changyun Hu, Hao Cai, Danielle M. DiCara, Yi-Chun Hsiao, Hai Ngu et al. · 2022 · Neurobiology of Disease
33. Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems
    Sameed Ahmed, Miandra Ellis, Hongshan Li, Luca Pallucchini, Andrew Marc Stein · 2019 · Journal of Pharmacokinetics and Pharmacodynamics
34. Calcitonin Gene‐Related Peptide Antagonists in the Treatment of Episodic Migraine
    Hsiangkuo Yuan, Courtney White, Stephen David Silberstein · 2019 · Clinical Pharmacology & Therapeutics
35. Determination of IL-23 Pharmacokinetics by Highly Sensitive Accelerator Mass Spectrometry and Subsequent Modeling to Project IL-23 Suppression in Psoriasis Patients Treated with Anti-IL-23 Antibodies
    Tingting Zhang, Junli Ma, Kenneth R. Durbin, Timothy J. Montavon, Susan E. Lacy, Gary J. Jenkins, Stella Z. Doktor, J. Cory Kalvass · 2019 · The AAPS Journal
36. Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologies
    Juraj Velcicky, Gregor S. Cremosnik, Clemens Scheufler, Peter J. Meier, Emmanuelle Wirth, Richard Felber, Paul Ramage, Michael Schaefer, Christian Kaiser, Sylvie Lehmann et al. · 2025 · Nature Communications
37. Quantitative Biodistribution of Biotherapeutics at Whole Body, Organ and Cellular Levels by Autoradiography
    Mengmeng Wang, Yutian Zhan, Shawn P. O’Neil, Stephen Harris, Claire Henson, Andrew McEwen, Rob Webster, Denise M. O’Hara · 2018 · Bioanalysis
38. Pharmacokinetic Characterization and Tissue Distribution of Fusion Protein Therapeutics by Orthogonal Bioanalytical Assays and Minimal PBPK Modeling
    Hiroshi Sugimoto, Susan Elizabeth Chen, Mark G. Qian · 2020 · Molecules
39. Developing a computational pharmacokinetic model of systemic snakebite envenomation and antivenom treatment
    Natalie M Morris, Johanna A. Blee, Sabine Hauert · 2022 · Toxicon
40. Pharmacokinetics of AAV9 Mediated Trastuzumab Expression in Rat Brain Following Systemic and Local Administration
    Ekram Ahmed Chowdhury, Manuj Ahuja, Shengjia Wu, Shufang Liu, Hsien Wei Huang, Mokshada Kumar, Kiran Sai Sunkara, Avanobe Ghobrial, Jayanth S. Chandran, Tanguy Jamier et al. · 2023 · Journal of Pharmaceutical Sciences
41. A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness
    David A. Plotnik, Jennifer E. Sager, Madhukar Aryal, Marie C. Fanget, Alessia Peter, Michael Schmid, Deborah Cebrik, Erik Mogalian, Keith Boundy, Wendy W. Yeh et al. · 2024 · Antimicrobial Agents and Chemotherapy
42. Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling
    Naruhisa Ota, C. Davies, Jing‐Qiong Kang, Donghong Yan, Alexis Scherl, Anne Wong, Ryan Cook, Xun Tao, Debra Y. Dunlap, Sha Klabunde et al. · 2025 · Proceedings of the National Academy of Sciences
43. Radioimmunotherapy Targeting B7-H3 in situ glioma models enhanced antitumor efficacy by Reconstructing the tumor microenvironment
    Meng Zheng, Yan Wang, Fengqing Fu, Kaijie Zhang, Yanan Wang, Shandong Zhao, Qingfeng Liu, Huiwen Mu, Xueguang Zhang, Liyan Miao · 2023 · International Journal of Biological Sciences
44. Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung
    Jamie Campbell, Josquin A Nys, Laura Eghobamien, E. Suzanne Cohen, Matthew J. Robinson, Matthew A. Sleeman · 2016 · mAbs
45. Impact of altered endogenous IgG on unspecific mAb clearance
    Saskia Fuhrmann, Charlotte Kloft, Wilhelm Huisinga · 2017 · Journal of Pharmacokinetics and Pharmacodynamics
46. Pharmacokinetic and pharmacodynamic study of a clinically effective anti‐CD2 monoclonal antibody
    Felix Sellberg, David Berglund, Christian Binder, James Hope, Jane A. Fontenot, Adam D. Griesemer, Megan Sykes, David H. Sachs, Erik Berglund · 2019 · Scandinavian Journal of Immunology
47. Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions
    Diana H. Marcantonio, Andrew Matteson, Marc Presler, John M. Burke, David Hagen, Fei Hua, Joshua F. Apgar · 2022 · Frontiers in Pharmacology
48. Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms
    De Sutter, Pieter-Jan, Gasthuys, Elke, Vermeulen, An · 2024 · Journal of Pharmacokinetics and Pharmacodynamics
49. Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic Response
    Evan S. Dellon, Matthew P. Kosloski, Arsalan Shabbir, Lila Glotfelty, Christine R. Xu, Mohamed A Kamal · 2024 · Clinical and Translational Gastroenterology
50. Development of Neutralizing Multimeric Nanobody Constructs Directed against IL-13: From Immunization to Lead Optimization
    Philippe J-L Y Gevenois, Pieter E.M. De Pauw, Steve Schoonooghe, Cédric Delporte, Thami Sebti, Karim Amighi, Serge Muyldermans, Nathalie Wauthoz · 2021 · The Journal of Immunology
51. Optimal imaging time points considering accuracy and precision of Patlak linearization for 89Zr-immuno-PET: a simulation study
    Jessica E. Wijngaarden, Marc C. Huisman, Johanna E. E. Pouw, C. Willemien Menke‐van der Houven van Oordt, Yvonne W. S. Jauw, Ronald Boellaard · 2022 · EJNMMI Research
52. Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
    Isabel H Gonzalez-Bocco, Katherine Beluch, Alyssa Cho, Chloé Lahoud, Fabiola A. Reyes, Dimitrios G Moshovitis, Gillian M. Unger-Mochrie, Wei Wang, Sarah Page Hammond, Jennifer Manne‐Goehler et al. · 2023 · Pilot and Feasibility Studies
53. A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs
    G Kapitanov, J Chabot, Jatin Narula, Mahua Roy, Hendrik Neubert, Joe Palandra, Vahid Farrokhi, Jay S. Johnson, Robert Webster, Hannah M. Jones · 2021 · Frontiers in Bioinformatics
54. Anticalin®-based therapeutics: Expanding new frontiers in drug development
    Aizea Morales‐Kastresana, Martin Siegemund, Stefan Haak, Janet K. Peper-Gabriel, Vanessa Neiens, Christine Rothe · 2022 · International review of cytology
55. Investigation of dose-exposure-response relationship for adeno-associated virus–mediated delivery of antibody genes
    Aneesh Rajwade, Shufang Liu, Mokshada Kumar, Avanobe Ghobrial, Sara Hahn, Dhaval K. Shah · 2025 · Journal of Pharmacology and Experimental Therapeutics
56. Progress in novel delivery technologies to improve efficacy of therapeutic antibodies
    Wenli Sun, Yanling Wu, Tianlei Ying · 2024 · Antiviral Research
57. Viral Kinetics Model of SARS‐CoV‐2 Infection Informs Drug Discovery, Clinical Dose, and Regimen Selection
    Allison Claas, Meelim J. Lee, Pai‐Hsi Huang, Charles G. Knutson, Domenico Bullara, Birgit Schoeberl, Suzanne Gaudet · 2024 · Clinical Pharmacology & Therapeutics
58. Development of a Specifically Labeled 89Zr Antibody for the Noninvasive Imaging of Tumors Overexpressing B7-H3
    Meng Zheng, Qingfeng Liu, Hua Zhang, Yanan Wang, Kaijie Zhang, Huiwen Mu, Fengqing Fu, Xueguang Zhang, Yan Wang, Liyan Miao · 2024 · Molecular Pharmaceutics
59. Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS‐CoV ‐2 neutralizing monoclonal antibody ABBV‐47D11 in patients with COVID ‐19
    Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh L. Tripathi, Joseph M. Reardon, John M. Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim et al. · 2022 · Pharmacology Research & Perspectives
60. Mini-PBPK-Based Population Model and Covariate Analysis to Assess the Complex Pharmacokinetics and Pharmacodynamics of RO7449135, an Anti-KLK5/KLK7 Bispecific Antibody in Cynomolgus Monkeys
    Hao Cai, Xun Tao, Jeongsup Shim, Rebecca N. Bauer, Meire C.D. Bremer, Wei Bu, Jason LaMar, Rachel Basile, Edward Dere, Tien V. Nguyen et al. · 2023 · The AAPS Journal
61. An oral protein cocktail therapeutic for C. difficile infection
    Hui Zhao, Michael Dodds, Alex Pollock, Mesfin M. Gewe, Anissa Martinez, Kristie M. Keeney, Benjamin W. Jester, Melanie L. Hutton, Hannah Tabakh, Mia Zhang et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
62. Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus
    Junyi Wu, Xuan Zhou, Richard J. Dimelow, Scott F. Marshall · 2024 · British Journal of Clinical Pharmacology
63. Building a potent TREM2 agonistic, biparatopic, common light chain antibody
    Adam R. Almeida, Melissa L. Geddie, Anil Bhate, Chao Quan, Joseph W. Arndt, Yang Jiao, Joseph C. Santoro, Liron Noiman, Ramya Vijayakumar, Jorge Sanchez-Salazar et al. · 2025 · mAbs
64. Research progress on nanobodies in the diagnosis and treatment of natural toxin poisoning
    Xiwei Wang, Zenglin Yin, Nan Liu, Hui Zhang, Zengming Wang, Jinjing Che, Jianchun Li, Aiping Zheng · 2025 · Nano Today
65. Translational pharmacokinetics of a novel bispecific antibody against Ebola virus (MBS77E) from animal to human by PBPK modeling & simulation
    Wenpeng Zhang, Yanan Xiang, Lingchao Wang, Furun Wang, Guanglu Li, Xiaomei Zhuang · 2022 · International Journal of Pharmaceutics
66. Passive immunization inhibits tau phosphorylation and improves recognition learning and memory in 3xTg-AD mice
    Longfei Li, Jin Miao, Yanli Jiang, Chun‐Ling Dai, Khalid Iqbal, Fei Liu, Dandan Chu · 2023 · Experimental Neurology
67. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies
    Monica E. Susilo, Stephan Schaller, Luis David Jiménez‐Franco, Alexander Jan Kulesza, Wilhelmus E. A. de Witte, Shang‐Chiung Chen, C. Andrew Boswell, Danielle Mandikian, Chi‐Chung Li · 2025 · Pharmaceutics
68. Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics
    Abdallah Derbalah, Felix Stader, Cong Liu, Adriana Żyła, Tariq Abdulla, Qier Wu, Masoud Jamei, Iain Gardner, Armin Sepp · 2025 · Journal of Pharmacokinetics and Pharmacodynamics
69. Virtual patients inspired by multiomics predict the efficacy of an anti-IFNα mAb in cutaneous lupus
    Vincent J. Hurez, Glenn Gauderat, Perrine Soret, Renee Myers, Krishnakant Dasika, Robert Sheehan, Christina M. Friedrich, Mike Reed, Laurence Laigle, Marta Alarcón Riquelme et al. · 2025 · iScience
70. Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection
    Aruni Jha, Douglas Barker, Jocelyne M. Lew, Vinoth K. Manoharan, Jill van Kessel, Robert E. Haupt, Derek Toth, Matthew B. Frieman, Darryl Falzarano, Shantha Kodihalli · 2022 · Scientific Reports
71. Non-invasive strategy: Developing a topical IL-4Rα-specific nanobody for the treatment of allergic airway diseases
    Taeyoung Ahn, Dong Hyuk Lee, Geun-Ah Kim, Jihyun Kim, Joon‐Sang Park, Hyung‐Ju Cho, Joo Young Kim · 2024 · Materials Today Bio
72. Abuse liability assessment for biologic drugs – All molecules are not created equal
    Christina L. Zuch de Zafra, Carrie G. Markgraf, David M. Compton, Thomas J. Hudzik · 2017 · Regulatory Toxicology and Pharmacology
73. Contribution of Intrinsic Fluorescence to the Design of a New 3D-Printed Implant for Releasing SDABS
    Alexandre Nicolas, Alice Dejoux, Cécile Poirier, Nicolas Aubrey, Jean‐Manuel Péan, Florence Velge-Roussel · 2020 · Pharmaceutics
74. Development of a humanized anti-fibrin monoclonal antibody for the treatment of neuroinflammatory and retinal diseases
    Aaron B. Kantor, Mathias Rickert, Hank Cheng, Kenneth Flanagan, Vasudha Salgotra, Anjana Suppahia, Jae Kyu Ryu, Paul Widboom, Joseph R. Warfield, Katerina Akassoglou et al. · 2025 · Journal of Neuroinflammation
75. Assessment of Epithelial Lining Fluid Partitioning of Systemically Administered Monoclonal Antibodies in Rats
    Elin Boger, Teodor Erngren, Britt‐Marie Fihn, Emilyanne Leonard, Katarina Rubin, Erica Bäckström · 2023 · Journal of Pharmaceutical Sciences
76. Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial
    Benjamin Jean Gaborit, Bernard Vanhove, Karine Lacombe, Thomas Guimard, Laurent Hocqueloux, Ludivine Perrier, Vincent Dubée, Virginie Ferré, Céline Bressollette‐Bodin, Régis Josien et al. · 2023 · Open Forum Infectious Diseases
77. Comparison of dose selection based on target engagement versus inhibition of receptor–ligand interaction for checkpoint inhibitors
    Sarah A. Head, Carter Johnson, Saheli Sarkar, Andrew Matteson, Diana H. Marcantonio, Fei Hua, John M. Burke, Joshua F. Apgar, David A. Flowers · 2024 · CPT Pharmacometrics & Systems Pharmacology
78. Engineered B7-H3-targeted VHH-Fc fusion antibody demonstrates rapid tumor accumulation for infrared imaging in pancreatic cancer xenograft model
    Xiaofei Mo, Yuqing Xu, Fengfeng Han, Yuetao Wang, Mingge Zhou, Chen He · 2025 · Bioorganic & Medicinal Chemistry
79. Bi-functional integrin degraders cause stronger anti-proliferative effects than a blocking antibody by modulating distinct downstream signaling
    Meghan Monroy, Megan T. Krumpoch, T. Andrew McTeague, Angela Fee, Dooyoung Lee, Zhaohui Sunny Zhou, Fu‐Yang Lin · 2025 · mAbs
80. Single-Domain Antibody Probe with Low Renal Uptake for Claudin 18.2Targeted PET Imaging of Gastric Cancer: Preclinical and Pilot Clinical Evaluations
    Meng Zheng, Haoqun Ma, Tao Xu, Huiwen Mu, Qingfeng Liu, Kaijie Zhang, Yicong Bian, Hua Zhang, Wei Li, Bin Zhang et al. · 2026 · Journal of Nuclear Medicine
81. CGRP Therapeutics For The Treatment Of Migraine – A Narrative Review
    Hsiangkuo Yuan · 2020
82. A multi‐model approach to predict efficacious clinical dose for an anti‐TGF ‐β antibody ( GC2008 ) in the treatment of osteogenesis imperfecta
    Panteleimon D. Mavroudis, Nikhil Pillai, Qingping Wang, Clemence Pouzin, Benjamin Greene, Jennifer Fretland · 2022 · CPT Pharmacometrics & Systems Pharmacology
83. The in vitro and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2
    Dong-Kyun Ryu, Hye‐Min Woo, Bobin Kang, Hanmi Noh, Jong‐In Kim, Ji-Min Seo, Cheol-Min Kim, Minsoo Kim, Jun‐Won Kim, Nayoung Kim et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
84. Development of a New Method to Evaluate the Biodistribution of Antibodies Using Non-Radioactive Metal Labeling and Inductively Coupled Plasma Mass Spectrometry
    Miho Nagayasu, Yoko Takano, Kazuhisa Ozeki · 2023 · Pharmaceutical Research
85. Absorption, Distribution, Metabolism and Excretion of Biopharmaceutical Drug Products
    Molly Graveno, Robert E. Stratford · 2024 · Springer eBooks
86. Breadth of Pharmacology Modeling: Fundamentals of Pharmacokinetics, Pharmacodynamics, and Mechanistic Modeling
    Donald E. Mager · 2025 · Handbook of experimental pharmacology
87. Alternative Binding Scaffolds: Multipurpose Binders for Applications in Basic Research and Therapy
    Doreen Könning, Jonas V. Schaefer · 2020 · Learning materials in biosciences
88. Treatment of highly virulent mammarenavirus infections—status quo and future directions
    Ivette A. Nuñez, Anya Crane, Ian Crozier, Gabriella Worwa, Jens H. Kuhn · 2024 · Expert Opinion on Drug Discovery
89. An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
    Di Zhou, Roman Kischel, Sabine Stienen, Danielle Townsley, Alexander Sternjak, Michael Lutteropp, Julie M. Bailis, Matthias Friedrich, Benno Rattel, Khamir Mehta et al. · 2024 · Clinical Pharmacology & Therapeutics
90. Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics
    Jasmine P. Davda, Kellie S. Reynolds, John D. Davis, Patrick F. Smith · 2021 · British Journal of Clinical Pharmacology
91. Pharmacokinetic profiles of a SARS‐COV‐2 neutralizing antibody BD‐604 in cynomolgus monkeys
    Feng Gao, Xu Zhang · 2021 · Drug Testing and Analysis
92. Target‐Driven Pharmacokinetics of Biotherapeutics
    Wilhelm Huisinga, Saskia Fuhrmann, Ludivine Fronton, Ben‐Fillippo Krippendorff · 2015 · Pharmaceutical Sciences Encyclopedia
93. Pharmacokinetics of Antibody–Drug Conjugates
    Amrita V. Kamath · 2016
94. Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations
    Celeste Vallejo, Cameron Meaney, Lara Clemens, Kyunghee Yang, Viera Lukáčová, Haiying Zhou · 2025 · Pharmaceutics
95. Monotherapy with antibody 1C3 partially protects Ebola virus-exposed macaques
    Gabriella Worwa, Carl W. Davis, Sarah E. Klim, Jacquelyn Turcinovic, Krystle N. Agans, Viktoriya Borisevich, Joan B. Geisbert, Robert W. Cross, Anya Crane, Michael R. Holbrook et al. · 2025 · Journal of Virology
96. A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies
    Georgi I. Kapitanov, David A. Flowers, Diana H. Marcantonio, Timothy R. Lezon, Joshua F. Apgar, Fei Hua · 2025 · CPT Pharmacometrics & Systems Pharmacology
97. Nonspecific Cellular Interactions Are a Key Determinant in the Disposition of Fc-Fused Proteins
    Mark A. Bryniarski, Songyu Wang, Aochiu Chen, Brian Coventry, Elif Nihal Korkmaz, Md Tariqul Haque Tuhin, Eunkyung Clare Ko, Devin L. Wakefield, Edward L. LaGory, Hao Wu et al. · 2026 · Molecular Pharmaceutics
98. Pharmacokinetic modeling to optimize development and therapeutic potential of mAb-based therapies
    Xiaoqing Fan, Chengcong Chen, Lin Zhang, Kangna Cao, Xiaoyu Yan · 2026 · Advanced Drug Delivery Reviews
99. 14th Annual Meeting of the Safety Pharmacology Society: Threading through peripheral and central nervous system presentations
    Icilio Cavero, Henry H. Holzgrefe · 2015 · Journal of Pharmacological and Toxicological Methods
100. A strategy to design protein-based antagonists against type I cytokine receptors
     Timo Ullrich, Olga Klimenkova, Christoph Pollmann, Asma Lasram, Valeriia Hatskovska, Kateryna Maksymenko, M. Milijaš-Jotić, Lukas SCHENK, Claudia Lengerke, Marcus D. Hartmann et al. · 2024 · PLoS Biology